Screening for ASXL1 and SRSF2 mutations is imperative for treatment decision-making in otherwise low or intermediate-1 risk patients with myelofibrosis

Ayalew Tefferi, Terra L. Lasho, Curtis A. Hanson, Rhett P. Ketterling, Naseema Gangat, Animesh D Pardanani

Research output: Contribution to journalArticle

5 Citations (Scopus)
Original languageEnglish (US)
JournalBritish Journal of Haematology
DOIs
StateAccepted/In press - Jan 1 2017

Fingerprint

Primary Myelofibrosis
Decision Making
Transplants
Mutation
Therapeutics

Keywords

  • Allogeneic
  • Primary myelofibrosis
  • Prognosis
  • Survival
  • Transplant

ASJC Scopus subject areas

  • Hematology

Cite this

Screening for ASXL1 and SRSF2 mutations is imperative for treatment decision-making in otherwise low or intermediate-1 risk patients with myelofibrosis. / Tefferi, Ayalew; Lasho, Terra L.; Hanson, Curtis A.; Ketterling, Rhett P.; Gangat, Naseema; Pardanani, Animesh D.

In: British Journal of Haematology, 01.01.2017.

Research output: Contribution to journalArticle

@article{69587aa029874679afd3bf6886b534c1,
title = "Screening for ASXL1 and SRSF2 mutations is imperative for treatment decision-making in otherwise low or intermediate-1 risk patients with myelofibrosis",
keywords = "Allogeneic, Primary myelofibrosis, Prognosis, Survival, Transplant",
author = "Ayalew Tefferi and Lasho, {Terra L.} and Hanson, {Curtis A.} and Ketterling, {Rhett P.} and Naseema Gangat and Pardanani, {Animesh D}",
year = "2017",
month = "1",
day = "1",
doi = "10.1111/bjh.15010",
language = "English (US)",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "Wiley-Blackwell",

}

TY - JOUR

T1 - Screening for ASXL1 and SRSF2 mutations is imperative for treatment decision-making in otherwise low or intermediate-1 risk patients with myelofibrosis

AU - Tefferi, Ayalew

AU - Lasho, Terra L.

AU - Hanson, Curtis A.

AU - Ketterling, Rhett P.

AU - Gangat, Naseema

AU - Pardanani, Animesh D

PY - 2017/1/1

Y1 - 2017/1/1

KW - Allogeneic

KW - Primary myelofibrosis

KW - Prognosis

KW - Survival

KW - Transplant

UR - http://www.scopus.com/inward/record.url?scp=85034988932&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85034988932&partnerID=8YFLogxK

U2 - 10.1111/bjh.15010

DO - 10.1111/bjh.15010

M3 - Article

JO - British Journal of Haematology

JF - British Journal of Haematology

SN - 0007-1048

ER -